Jazz Pharmaceuticals, Inc. earnings per share and revenue
On Nov 05, 2025, JAZZ reported earnings of 8.13 USD per share (EPS) for Q3 25, beating the estimate of 6.03 USD, resulting in a 34.65% surprise. Revenue reached 1.13 billion, compared to an expected 1.13 billion, with a -0.41% difference. The market reacted with a -2.31% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 18 analysts forecast an EPS of 6.53 USD, with revenue projected to reach 1.18 billion USD, implying an decrease of -19.68% EPS, and increase of 4.47% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
Dec 22, 2025 For Q4 25
Estimate
-$0.57
Actual
-$0.73
Surprise
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
Dec 19, 2025 For Q4 25
Estimate
-$0.25
Actual
-$0.19
Surprise
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
Dec 23, 2025 For Q4 25
Estimate
-$0.12
Actual
-$0.06
Surprise
+50.98%
FAQ
What were Jazz Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Jazz Pharmaceuticals, Inc. reported EPS of $8.13, beating estimates by 34.65%, and revenue of $1.13B, -0.41% below expectations.
How did the market react to Jazz Pharmaceuticals, Inc.'s Q3 2025 earnings?
The stock price moved down -2.31%, changed from $137.22 before the earnings release to $134.05 the day after.
When is Jazz Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Feb 23, 2026.
What are the forecasts for Jazz Pharmaceuticals, Inc.'s next earnings report?
Based on 18
analysts, Jazz Pharmaceuticals, Inc. is expected to report EPS of $6.53 and revenue of $1.18B for Q4 2025.